Heteroaromatic compounds as PI3 kinase modulators and methods of use
View Patent ↗The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
1. A compound of Formula (I):
or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically salt or a prodrug thereof, wherein:
each of W 1 , W 2 and W 3 is independently N or CR c ;
Z is D, CN, N 3 or
X is H, D, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl or 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N 3 , OR a , SR a , NR a R b , —C(═O)NR a R b , (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —(C 1 -C 4 )alkylene-CN, —(C 1 -C 4 )alkylene-OR a , —(C 1 -C 4 )alkylene-NR a R b , (C 6 -C 10 )aryl and 5-10 membered heteroaryl;
Y is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl or 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N 3 , OR a , SR a , NR a R b , —C(═O)NR a R b , (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —(C 1 -C 4 )alkylene-CN, —(C 1 -C 4 )alkylene-OR a , —(C 1 -C 4 )alkylene-NR a R b , (C 6 -C 10 )aryl and 5-10 membered heteroaryl;
R 1 is H, D, Cl, OR a , NR a R b , (C 1 -C 6 )aliphatic or (C 3 -C 6 )cycloalkyl, wherein each of the (C 1 -C 6 )aliphatic and (C 3 -C 6 )cycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OR a , SR a and NR a R b , provided that when each of W 1 , W 2 and W 3 is CH, R 1 is not H or NH 2 ;
each R a and R b is independently H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl); or when R a and R b are bonded to the same nitrogen atom, R a and R b , together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered heterocyclic ring, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )alkoxy, and (C 1 -C 6 )alkylamino; and
each R c is independently H, D, F, Cl, Br, I, N 3 , CN, OH, NH 2 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylamino, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl or 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, wherein each of the (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylamino, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino.
2. The compound according to claim 1 , wherein each of W 1 and W 2 is independently N or CR c , W 3 is CR c .
3. The compound according to claim 1 , wherein Z is CN, N 3 or
4. The compound according to claim 1 , wherein X is H, D, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl or —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl and —(C 1 -C 4 )alkylene-(C 3 -C 6 ) heterocyclyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N 3 , OR a , SR a , NR a R b , —C(═O)NR a R b , (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 2 -C 6 )alkenyl and (C 2 -C 6 )alkynyl.
5. The compound according to claim 1 , wherein Y is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl or 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, Br, CN, N 3 , OR a , SR a , NR a R b , —C(═O)NR a R b , (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl and 5-10 membered heteroaryl.
6. The compound according to claim 1 , wherein R 1 is H, D, Cl, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OCH 3 , OCH 2 CH 3 , NH 2 , NHCH 3 or N(CH 3 ) 2 , provided that when each of W 1 , W 2 and W 3 is CH, R 1 is not H or NH 2 .
7. The compound according to claim 1 , wherein each R c is independently H, D, F, Cl, N 3 , CN, NH 2 , (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkylamino, (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )heterocyclyl, wherein each of the (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkylamino, (C 3 -C 6 )cycloalkyl and (C 3 -C 6 )heterocyclyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, CN, N 3 , OH, NH 2 , (C 1 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl and (C 1 -C 3 )haloalkyl.
8. The compound according to claim 1 having one of the following structures:
9. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.
10. The pharmaceutical composition according to claim 9 further comprising an additional therapeutic agent which comprising a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis or a combination thereof.
11. The pharmaceutical composition according to claim 10 , wherein the additional therapeutic agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozocin, cisplatin, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbazine, methotrexate, fluorouracil, cytarabine, gemcitabine, mercaptopurine, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, epirubicin, daunorubicin, mitoxantrone, bleomycin, mitomycin, ixabepilone, tamoxifen, flutamide, gonadorelin analogues, megestrol, prednidone, dexamethasone, methylprednisolone, thalidomide, interferon alfa, leucovorin, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, ramucirumab, rituximab, tositumomab, trastuzumab, or a combination thereof.
12. A method of treating or lessening the severity of a proliferative disorder in a patient by administering to the patient the compound according to claim 1 , wherein the proliferative disorder is glioblastoma.
13. A method of treating or lessening the severity of a proliferative disorder in a patient by administering to the patient the pharmaceutical composition according to claim 9 , wherein the proliferative disorder is glioblastoma.
14. A method of inhibiting or modulating the activity of a protein kinase in a biological sample comprising contacting a biological sample with the compound according to claim 1 .
15. The method of claim 14 , wherein the protein kinase is a receptor tyrosine kinase.
16. The method of claim 15 , wherein the receptor tyrosine kinase is PI3K, mTOR or a combination thereof.
17. A method of inhibiting or modulating the activity of a protein kinase in a biological sample comprising contacting a biological sample with the pharmaceutical composition according to claim 9 .
18. The method of claim 17 , wherein the protein kinase is receptor tyrosine kinase.
19. The method of claim 18 , wherein the receptor tyrosine kinase is PI3K, mTOR or a combination thereof.